BloodHow I Prevent Viral Reactivation in High-risk Patients

An essential component of successfully enhancing transplant outcomes is early viral infection prevention. Clinically severe viral infections have been successfully avoided in hematopoietic cell transplant patients with prophylactic and preventive therapy with antiviral medications. Through a better understanding of the biology and risk factors, the introduction of novel antiviral agents, and developments in immunotherapy, significant progress has been made in the past few decades in preventing viral infections. There is solid proof that herpes simplex virus, varicella-zoster virus, and CMV infection and illness can be prevented. There is a dearth of information on how to effectively prevent infections with human herpesvirus 6, Epstein-Barr virus, adenovirus, and BK virus.